Navigation Links
Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer
Date:5/31/2008

tara trial to the next stage," said Dr. Kevin Judy, associate professor neurosurgery at the University of Pennsylvania School of Medicine and a principal investigator of the Cotara dosimetry trial. "Cotara's good safety profile to date is especially encouraging in view of the toxicity of the treatment options currently available to GBM patients. We look forward to further assessing its safety and anti-tumor activity at the higher doses we plan to use in the next stages of the trial."

The open label dose confirmation and dosimetry study at U.S. brain cancer centers is enrolling GBM patients with recurrent disease. Patients in this trial receive an initial imaging dose of Cotara before receiving the therapeutic dose.

"These positive data validate a key principle underlying the Cotara program, confirming its ability to specifically concentrate in and deliver a high radiation dose to brain tumors," said Steven W. King, president and CEO of Peregrine. "These results also further confirm the key targeting attribute of Cotara, showing it results in minimal radiation exposure to other organs, including the thyroid. We also are encouraged that patients in this initial, low-dose cohort have already lived longer than the expected median survival time for GBM patients at first relapse, and we look forward to reporting further data on Cotara in the coming months."

The dosimetry study's main objectives are to confirm the maximum tolerated dose of Cotara, to determine radiation dosimetry and to assess overall patient survival, progression-free survival and the proportion of patients alive at six months following Cotara administration. In addition to the University of Pennsylvania Medical Center, the Medical University of South Carolina in Charleston and the Barrow Neurological Institute in Phoenix, Arizona are participating in the trial. A fourth study site was recently initiated at Case Western Reserve University in Cleveland, Ohio. Peregrine is also conducti
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
2. Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
3. Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
4. Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis
5. Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW
6. New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nations Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
7. Eisais Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting
8. New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients
9. XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
10. Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
11. Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015  Mallinckrodt plc (NYSE: MNK ) announced ... share repurchase program. The open-ended authorization permits the company ... ordinary shares. "Funding additional initiatives and ... we continue to pursue a range of focused growth ...
(Date:1/23/2015)... BOSTON , January 23, 2015 Heptares ... is delighted to announce that the Malcolm Campbell ... Congreve (Vice President of Chemistry), Fiona Marshall ... (Chief Executive Officer and co-founder) for the seminal contributions to ...
(Date:1/22/2015)... a privately held medical device company, announced today that ... ITOCHU Corporation (Tokyo Stock Exchange TYO: 8001) to sell ... cancer in Japan . ViewRay,s technology, ... only MRI-guided radiation therapy system that images and treats ...
Breaking Medicine Technology:Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2
(Date:1/22/2015)... Plainsboro, NJ (PRWEB) January 22, 2015 ... advocate and keynote speaker at the upcoming 32nd ... by ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , ... breast would have gone undetected if she had not ...
(Date:1/22/2015)... 23, 2015 Recently, Weddingshe.com has added many ... has announced its highest annual revenues in the past three ... popular glamorous wedding dresses. , According to the sales manager ... dress promotions for them in 2015. This point can be ...
(Date:1/22/2015)... DC (PRWEB) January 22, 2015 Payday ... in vulnerable communities and cause financial distress to the ... by analysts at Howard University’s Center on Race and ... dollars in economic activity, payday loans at the same ...
(Date:1/22/2015)... JJsHouse.com is a famous dress online store ... announces its latest collection of wedding dresses , and ... issue is the wedding dress on your big day; the ... life. Every bride wants to find the most suitable wedding ...
(Date:1/22/2015)... 22, 2015 Step into a macabre ... Science Museum of Virginia. Wicked Plants, the Museum’s latest ... unearths 75 poisonous, carnivorous and diabolical plants inside of ... to uncover the biochemical, physical and neurological processes between ...
Breaking Medicine News(10 mins):Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... 6 In a newly-published special supplement, the Journal ... prevent and treat venous thromboembolism (VTE), a major cause ... Lippincott Williams & Wilkins (LWW) is publishing ... that includes both the common medical condition of deep ...
... statement in observance of Pancreatic Cancer Awareness Month , WASHINGTON, ... yet it is the fourth leading cause of death by cancer ... be diagnosed with the disease and more than 35,000 will die ... find a cure for pancreatic cancer researchers have to know more ...
... role in boosting memories -- or forgetting them, researchers say ... remember the first time you smelled a type of flower? ... brain might. , In the study, published online Nov. ... objects to adult study participants. They paired the objects with ...
... small group of patients with severe Graves, eye disease ... vision following treatment with the drug rituximab. Inflammation ... were significantly reduced. The same patients had not previously ... disease. Raymond S. Douglas, M.D., Ph.D., an oculoplastics ...
... TORONTO, On November 6, 2009 Researchers at St. ... fire services across Ontario found that a bystander who attempts ... 50 per cent. But Dr. Laurie Morrison and the research ... per cent of bystanders in Toronto are willing to help, ...
... , COLUMBUS, Ohio, Nov. 6 The Ohio Association of ... health care premiums and less robust benefits if proposals being ... were to become law. , If the reforms proposed by ... in Ohio would increase 60% over five years in the ...
Cached Medicine News:Health News:Journal of Cardiovascular Nursing Urges Policies and Prevention To Reduce Deaths from Venous Thromboembolism 2Health News:Journal of Cardiovascular Nursing Urges Policies and Prevention To Reduce Deaths from Venous Thromboembolism 3Health News:New Smells 'Etched' in Brain: Study 2Health News:Researchers find new way to attack inflammation in Graves' eye disease 2Health News:Less than 1 in 3 Toronto bystanders who witness a cardiac arrest try to help: Study 2Health News:Less than 1 in 3 Toronto bystanders who witness a cardiac arrest try to help: Study 3Health News:Congressional Health Care Reform Proposals Will Make Health Care More Expensive, Less Robust for Ohioans 2
The latest MAX MARA eyewear collection has evolved into a harmonious balance of tradition and,leading-edge trend, interpreting timeless themes in an absolutely modern way, yet never losing sight,...
Inquire...
Inquire...
... The collection features a range of ... most modern materials and producted to ... collection includes several super lightweight Titanium ... as a whole host of beautifully ...
Medicine Products: